Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$3.01 - $3.87 $241,182 - $310,091
80,127 New
80,127 $265,000
Q1 2022

May 12, 2022

SELL
$1.28 - $1.83 $551,101 - $787,902
-430,548 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$1.09 - $1.66 $139,307 - $212,156
127,805 Added 42.22%
430,548 $607,000
Q3 2021

Nov 12, 2021

SELL
$1.13 - $1.65 $77,611 - $113,326
-68,683 Reduced 18.49%
302,743 $342,000
Q2 2021

Aug 10, 2021

BUY
$1.51 - $2.07 $85,808 - $117,631
56,827 Added 18.06%
371,426 $594,000
Q1 2021

May 12, 2021

BUY
$1.67 - $2.95 $264,330 - $466,931
158,282 Added 101.26%
314,599 $554,000
Q4 2020

Feb 10, 2021

BUY
$1.8 - $2.56 $208,832 - $297,006
116,018 Added 287.89%
156,317 $305,000
Q3 2020

Nov 12, 2020

BUY
$2.04 - $3.74 $49,119 - $90,051
24,078 Added 148.44%
40,299 $96,000
Q2 2020

Aug 13, 2020

SELL
$2.42 - $3.29 $169,070 - $229,852
-69,864 Reduced 81.16%
16,221 $48,000
Q1 2020

May 13, 2020

SELL
$1.5 - $4.59 $11,937 - $36,527
-7,958 Reduced 8.46%
86,085 $248,000
Q4 2019

Feb 10, 2020

BUY
$3.89 - $5.15 $99,879 - $132,231
25,676 Added 37.56%
94,043 $376,000
Q3 2019

Nov 12, 2019

BUY
$3.19 - $5.39 $149,282 - $252,235
46,797 Added 216.95%
68,367 $304,000
Q2 2019

Aug 09, 2019

BUY
$3.52 - $5.24 $27,702 - $41,238
7,870 Added 57.45%
21,570 $83,000
Q1 2019

May 13, 2019

BUY
$2.61 - $4.35 $33,669 - $56,114
12,900 Added 1612.5%
13,700 $52,000
Q4 2018

Feb 06, 2019

SELL
$2.17 - $6.12 $12,803 - $36,108
-5,900 Reduced 88.06%
800 $2,000
Q3 2018

Nov 08, 2018

BUY
$4.39 - $6.85 $29,412 - $45,895
6,700 New
6,700 $5,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $3.03B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.